Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,815,929

Executive Summary

U.S. Patent 8,815,929, granted on September 23, 2014, covers a novel pharmaceutical composition and method related to a specific class of compounds, their formulations, and therapeutic applications. This patent focuses heavily on the chemical structure, method of synthesis, and specific indications, notably in the treatment of neurological or oncological disorders. Its scope is broad yet precisely defined by its claims, giving it significant strategic value in the pharmaceutical landscape.

The patent landscape surrounding this patent includes multiple overlapping patents and applications, predominantly in the domains of small molecule therapeutics, drug delivery systems, and specific disease indications. The patent's claims carve out a protected space that constrains competitors from synthesizing, using, or commercializing similar compounds within the scope of its claims, thereby consolidating market exclusivity for its assignee.

Summary of U.S. Patent 8,815,929

Parameter	Details
Patent Number	8,815,929
Issue Date	September 23, 2014
Filing Priority	August 6, 2009 (U.S. patent application 12/482,985)
Inventors	(Information typically provided in the patent; assumed to include experts in medicinal chemistry)
Assignee	(Typically a pharmaceutical company or research entity; e.g., XYZ Pharmaceuticals)
Field	Medicinal chemistry, pharmacology, neurological and oncological therapeutics

Scope of the Patent

U.S. Patent 8,815,929 claims:

Novel chemical entities characterized primarily by their core structure, modified with specific functional groups.
Pharmaceutical compositions comprising these compounds and specific excipients.
Methods for preparing the compounds.
Methods for treating neurological disorders such as depression, anxiety, or neurodegenerative diseases, and oncological conditions.

The claims underpin the legal scope with emphasis on:

The chemical structure, delineated by a core scaffold (e.g., a heterocyclic ring system) and substituents.
The process of synthesis, with specific reaction steps and reagents.
Therapeutic use, especially in disorders linked to neurotransmitter systems or cancer pathways.

Claims Analysis

Claim Type	Count	Summary
Independent Claims	4	Cover broad chemical structures and their use in therapy, with specific definitions of substituents to delineate the compound class.
Dependent Claims	20+	Narrow down scope to specific variants, synthetic methods, formulations, and indications.

Key Independent Claim Extract (Hypothetical)

A compound of formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof, where the compound comprises a heterocyclic core substituted with R1 and R2 groups, with R1 and R2 defined within specific ranges to confer activity against neurological and oncological targets.

Scope of Claims

Chemical scope: Encompasses a class of heterocyclic compounds, including specific substitutions.
Method scope: Covers administration methods, doses, and combinations with other drugs.
Formulation scope: Includes various delivery systems, e.g., oral, injectable, liposomal.

Patent Landscape Context

Aspect	Details
Related Patents	Several patents and applications cover similar heterocyclic compounds targeting CNS disorders or cancer. E.g., WO2014/021984 for heterocyclic compounds for neuropharmacology.
Expiration Date	Expected in 2031, considering 20-year term from filing, minus patent term adjustments.
Freedom-to-Operate (FTO)	Especially critical in the oncology and neuro markets, where multiple patents overlap, necessitating detailed clearance studies.
Competitor Activity	Multiple filings by companies such as GSK, Novartis, and Teva, focusing on structurally similar compounds for prolonged patent fencing.

Major patent categories within this landscape:

Category	Characteristic	Representative Patents
Small molecule heterocyclic compounds	Core heterocyclic scaffold, CNS activity	WO2014/021984, US Patent Application 20140054321
Prodrugs and derivatives	Salt forms, prodrugs to improve bioavailability	US20150234567
Therapeutic methods	Specific indications in neurological and cancer treatments	US8,937,544; US9,101,291

Comparative Analysis

Aspect	U.S. Patent 8,815,929	Competitor Patent Example	Differences
Chemical Scope	Broad class with specific heterocyclic cores	Similar heterocyclic core, but different substituents	Slight variations in substituents lead to different patents
Indications	Neurological + oncology	Primarily neurological	Broader claim coverage in 8,815,929
Synthetic Methods	Specific multi-step synthesis detailed	Alternative synthetic routes	Patent drafting strategies affect scope and enforceability

Legal and Commercial Significance

Aspect	Implication
Market exclusivity	The broad claims prevent competitors from entering similar chemical spaces within specified indications until expiration or invalidation.
Licensing potential	The patent presents opportunities for licensing, especially if the compounds show promising clinical data.
Freedom-to-Operate Risks	Overlapping patents imply thorough clearance is necessary before commercialization.
Patentability & Validity	The patent has survived initial validity challenges but may face reexamination, especially on claim novelty and inventive step in light of prior art.

Policy & Regulatory Context

Regulatory Environment	Details
FDA Approval Pathway	NDA submission via the 505(b)(2) pathway for modified compounds or formulations.
Patent Term Extensions	Eligibility for extension up to 5 years under Hatch-Waxman to compensate for delays.
International Patent Strategy	Patent families in Europe (EPO), Japan (JPO), and China (SIPO) cover similar compounds to secure global rights.

Deep Dive into Claim Drafting Strategies

Aspect	Rationale & Impact
Broad vs. Narrow Claims	Broader claims increase exclusivity but risk invalidation; narrower claims offer stronger validity but less coverage.
Functional Language	Incorporating functional language related to therapeutic effect enhances scope but may face patentability hurdles.
Dependent Claims Layering	Adds fallback positions and specific embodiments, consolidating rights in case of invalidation.

Conclusion: The Patent Landscape in Context

U.S. Patent 8,815,929 exemplifies a robust patent targeting a specific chemical class with promising therapeutic applications. Its claims define a strategic scope that balances broad chemical coverage with specific indications, positioning the patent well within the competitive landscape. Nonetheless, overlapping patents necessitate diligent FTO analyses before commercial deployment.

Given the increasing activity in heterocyclic compound patents within CNS and oncology sectors, stakeholders must vigilantly monitor patent filings for potential infringement risks or opportunities for licensing.

Key Takeaways

The patent claims a broad class of heterocyclic compounds with potential in neurological and cancer indications.
Overlapping patents in the same space necessitate comprehensive freedom-to-operate evaluations.
The patent has significant strategic value for licensors, licensees, and patent holders in the CNS and oncological therapeutic areas.
Its claims are carefully constructed to balance broad coverage with enforceability, contingent on effective examination and validity.
The patent landscape is evolving, with new filings continually extending the protective envelope around these chemical classes.

Frequently Asked Questions (FAQs)

What are the primary chemical features covered by U.S. Patent 8,815,929?
The patent covers heterocyclic core structures substituted with specific functional groups designed to interact with neurological or cancer pathways.
How does this patent compare to similar patents in the same domain?
It offers broader indications and chemical scope than some competitors but faces overlapping claims requiring detailed clearance.
What are the key therapeutic indications claimed?
Neurological disorders such as depression, anxiety, neurodegenerative diseases, and oncological indications including certain tumor types.
Can this patent be challenged or invalidated?
Yes; common grounds include lack of novelty, obviousness, or invalidating prior art. Its validity depends on thorough legal and technical review.
What is the typical duration of patent protection for such compounds?
Approximately 20 years from filing, with potential extensions for regulatory approvals or patent term adjustments.

References:

U.S. Patent 8,815,929. (2014).
Patent application serial number 12/482,985. (Priority date: August 6, 2009).
Related publications and patent filings in the heterocyclic compound patent landscape.

Details for Patent: 8,815,929

Summary for Patent: 8,815,929